Boehringer Ingelheim Pharma GmbH & Co. KG

A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug–Drug–Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals (2020) Hanke N, Türk D, Selzer D, Ishiguro N, Ebner T, Wiebe S, Müller F, et al. Journal article Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases (2020) Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Abraham A, Althaus K, et al. Journal article Shared and distinct mechanisms of fibrosis (2019) Distler J, Györfi AH, Ramanujam M, Whitfield ML, Königshoff M, Lafyatis R Journal article, Review article In Vivo Protein Complementation Demonstrates Presynaptic α-Synuclein Oligomerization and Age-Dependent Accumulation of 8–16-mer Oligomer Species (2019) Kiechle M, von Einem B, Höfs L, Voehringer P, Grozdanov V, Markx D, Parlato R, et al. Journal article Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial (2019) Highland K, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, et al. Conference contribution Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial (2019) Mayes M, Highland K, Gahlemann M, Fischer A, Raghu G, Girard M, Alves M, et al. Conference contribution The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases (2019) Matteson E, Kelly C, Distler J, Mann-Vold AMH, Seibold J, Mittoo S, Distler O, et al. Conference contribution The Effect of Nintedanib versus Mycopheolate Mofetil in the FRA2 Mouse Model of Systemic Sclerosis Associated Interstitial Lung Disease (2019) Thuong Trin-Minh , Zhang Y, Distler J, Wollin L Conference contribution A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours (2019) Krauss J, Eigentler T, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases (2019) Wollin L, Distler J, Redente EF, Riches DW, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M Journal article, Review article